Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology

Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology

Abstract Background The gastrin-releasing peptide receptor (GRPR) has been extensively studied as a biomolecular target for peptide-based radiotheranostics. However, the lack of metabolic stability and the rapid clearance of peptide radioligands, including radiolabeled GRPR-antagonists, often impede...

Full description

Bibliographic Details
Main Authors: Panagiotis Kanellopoulos, Adam Mattsson, Ayman Abouzayed, Karim Obeid, Berthold A. Nock, Vladimir Tolmachev, Theodosia Maina, Anna Orlova
Format: Article
Language:English
Published: SpringerOpen 2024-02-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
Prostate cancer
GRPR-antagonist
Radiotheranostics
PC-3 tumors
Metabolic stability
NEP-inhibition
Online Access:https://doi.org/10.1186/s41181-024-00242-6

Internet

https://doi.org/10.1186/s41181-024-00242-6

Similar Items